Can genetics predict who responds to heart failure treatment?

NCT ID NCT06435585

Recruiting now Knowledge-focused Sponsor: Karolinska University Hospital Source: ClinicalTrials.gov ↗

First seen Aug 10, 2026 · Last updated Aug 11, 2026 · Updated 1 time

Summary

This study aims to understand why some people with heart failure respond well to standard guideline-directed medical therapy while others do not. By analyzing genetic data and biomarkers from a large biobank of 5,000 patients, researchers hope to identify predictors of treatment response. The goal is to improve outcomes by tailoring treatment to individual patients, potentially reducing morbidity and mortality.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to: If successful, this could lead to personalized heart failure treatment, helping doctors predict which patients will benefit from standard therapies and which may need alternatives.
What could go wrong: This is an observational study, not a treatment trial, so it won't directly test a new drug. The findings may take years to translate into clinical practice, and genetic influences are complex and not fully understood.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEART FAILURE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

heart failure

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEART FAILURE PATHOPHYSIOLOGY

Contacts and locations

Locations

Karolinska University hospital
RECRUITING

Stockholm, 17164, Sweden

More trials for these conditions

Other studies related to the condition(s) this trial covers.